Literature DB >> 18434252

Relation of circulating concentrations of chemokine receptor CCR5 ligands to C-peptide, proinsulin and HbA1c and disease progression in type 1 diabetes.

C Pfleger1, A Kaas, L Hansen, B Alizadeh, P Hougaard, R Holl, H Kolb, B O Roep, H B Mortensen, N C Schloot.   

Abstract

Th1 related chemokines CCL3 and CCL5 and Th2 related CCL4 as ligands of the receptor CCR5 contribute to disease development in animal models of type 1 diabetes. In humans, no data are available addressing the role of these chemokines regarding disease progression and remission. We investigated longitudinally circulating concentrations of CCR5 ligands of 256 newly diagnosed patients with type 1 diabetes. CCR5 ligands were differentially associated with beta-cell function and clinical remission. CCL5 was decreased in remitters and positively associated with HbA1c suggestive of a Th1 associated progression of the disease. Likewise, CCL3 was negatively related to C-peptide and positively associated with the beta-cell stress marker proinsulin but increased in remitters. CCL4 associated with decreased beta-cell stress shown by negative association with proinsulin. Blockage of chemokines or antagonism of CCR5 by therapeutic agents such as maraviroc may provide a new therapeutic target to ameliorate disease progression in type 1 diabetes.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18434252     DOI： 10.1016/j.clim.2008.03.458

Source DB:  PubMed          Journal:  Clin Immunol        ISSN： 1521-6616            Impact factor:   3.969


  20 in total

Review 1.  Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetes.

Authors:  Bart O Roep; Mark Peakman
Journal:  Nat Rev Immunol       Date:  2010-02       Impact factor: 53.106

2.  Pro- and anti-inflammatory cytokines in latent autoimmune diabetes in adults, type 1 and type 2 diabetes patients: Action LADA 4.

Authors:  M N Pham; M I Hawa; C Pfleger; M Roden; G Schernthaner; P Pozzilli; R Buzzetti; W A Scherbaum; W Scherbaum; J Seissler; H Kolb; S Hunter; R D G Leslie; N C Schloot
Journal:  Diabetologia       Date:  2011-02-24       Impact factor: 10.122

3.  Simultaneous evaluation of the circulating levels of both Th1 and Th2 chemokines in patients with autoimmune Addison's disease.

Authors:  G Bellastella; M Rotondi; E Pane; S Costantini; C Colella; R Calemma; F Capone; A Falorni; G Castello; A A Sinisi; A Bizzarro; L Chiovato; A Bellastella; A De Bellis
Journal:  J Endocrinol Invest       Date:  2010-12-15       Impact factor: 4.256

4.  Fasting and meal-stimulated residual beta cell function is positively associated with serum concentrations of proinflammatory cytokines and negatively associated with anti-inflammatory and regulatory cytokines in patients with longer term type 1 diabetes.

Authors:  M N Pham; H Kolb; T Battelino; J Ludvigsson; P Pozzilli; F Zivehe; M Roden; T Mandrup-Poulsen; N C Schloot
Journal:  Diabetologia       Date:  2013-03-15       Impact factor: 10.122

5.  Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression.

Authors:  Christian Hundhausen; Alena Roth; Elizabeth Whalen; Janice Chen; Anya Schneider; S Alice Long; Shan Wei; Rebecca Rawlings; MacKenzie Kinsman; Stephen P Evanko; Thomas N Wight; Carla J Greenbaum; Karen Cerosaletti; Jane H Buckner
Journal:  Sci Transl Med       Date:  2016-09-14       Impact factor: 17.956

Review 6.  The role of inflammation in insulitis and beta-cell loss in type 1 diabetes.

Authors:  Décio L Eizirik; Maikel L Colli; Fernanda Ortis
Journal:  Nat Rev Endocrinol       Date:  2009-04       Impact factor: 43.330

7.  Fatty acids modulate cytokine and chemokine secretion of stimulated human whole blood cultures in diabetes.

Authors:  M C Simon; S Bilan; B Nowotny; T Dickhaus; V Burkart; N C Schloot
Journal:  Clin Exp Immunol       Date:  2013-06       Impact factor: 4.330

Review 8.  Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society.

Authors:  R Mallone; S I Mannering; B M Brooks-Worrell; I Durinovic-Belló; C M Cilio; F S Wong; N C Schloot
Journal:  Clin Exp Immunol       Date:  2010-10-05       Impact factor: 4.330

9.  A Novel Resolution of Diabetes: C-C Chemokine Motif Ligand 4 Is a Common Target in Different Types of Diabetes by Protecting Pancreatic Islet Cell and Modulating Inflammation.

Authors:  Ting-Ting Chang; Liang-Yu Lin; Jaw-Wen Chen
Journal:  Front Immunol       Date:  2021-04-23       Impact factor: 7.561

10.  The novel chemokine receptor, G-protein-coupled receptor 75, is expressed by islets and is coupled to stimulation of insulin secretion and improved glucose homeostasis.

Authors:  Bo Liu; Zoheb Hassan; Stefan Amisten; Aileen J King; James E Bowe; Guo Cai Huang; Peter M Jones; Shanta J Persaud
Journal:  Diabetologia       Date:  2013-08-27       Impact factor: 10.122
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.